It is impossible not to notice the enormous surge in human microbiome research currently underway around the world. For the past decade, new molecular methods have started to unlock the secrets of this unique bacterial universe. Building on work on how human individuals are not the dominant life form in the symbiosis of our bodies. It is already estimated that 90% are human and 10% microbial when a comparable count of cell numbers is taken into consideration; but perhaps more astonishingly, it is now clear that our human microbiome, the collection of genes encoded by our microbial passengers, is at least one hundred-fold greater than our own genome. The diversity of the human “microbiota” is enormous, with at least 500-1000 species existing in our gastrointestinal tracts alone. We are the vessels for this community of microbes (including bacteria, viruses, and yeasts) living on us and in us, and as we start to unravel the multitude of roles that this microbiota fulfils, it is becoming clear that our microbes play a far more relevant and important role in the maintenance of our health than we have ever stopped to consider before. Therefore, it stands to reason that we are at a pivotal point in our attitude towards microbes in a medical context.

ADJUSTING OUR PERCEPTION OF “GERMS”

From an early age most of us are taught that germs are bad and that we need to avoid them wherever possible. For clinicians, there is further reinforcement of this concept, from the threat of the nosocomial, small but significant number of microbes that are pathogenic to us. Infectious disease continues to be a major threat to health despite the medical advances we have made in the past few decades. The success of antibiotic therapy heralded a new era in our collective consciousness that, in the words of the US Surgeon General, William Stewart, in 1967, boldly suggested that it was time to “close the book on infectious disease.” The medical over-confidence that followed saw the use of antibiotics spread from the treatment of life-threatening infections to the treatment of less serious disease, from mild obstis media to acne. Now in 2014 we have realised the error of our ways, as we witness the widespread and increasing emergence of antibiotic-resistant microbes. Quite rightly, this is forcing a re-examination of the circumstances of antibiotic administration both in medical as well as environmental practices (for example, farming, where the Food and Drug Administration estimated the annual amount of non-therapeutic antibiotics administered to animals in the US in 2011 alone as 24.6 million lbs [almost 10.6 500 tonnes]) and encourage restriction on the use of these drugs whenever possible. However, the continuing study of the human microbiome is suggesting another, far more ominous side effect of antibiotic use: the concomitant loss of our resident microbiota. Our resident microbes are engaged in a complex partnership with our human selves that has co-evolved with us over millennia. These microbes have recently been revealed to have functions beyond their clear role as niche dwellers that competitively exclude pathogens. These functions vary widely across body sites and between resident microbes. The microbiota is known to educate the immune system, steering it away from needless attacks on commensal microbes such that its efforts can be concentrated on real threats. The gut microbiota also plays a role in breakdown of complex dietary components, provision of key molecules (including B vitamins), and even makes (as yet poorly understood) contributions to mood, behaviour and sleep patterns.

CONSEQUENCES OF COLLATERAL DAMAGE IN ANTIMICROBIAL THERAPY

Antimicrobials, and in particular those that are broad-spectrum in nature, are never simply targeted towards pathogens; in the battlefield of infection these drugs inflict heavy collateral damage on the indigenous microbiota. Fortunately, the microecology of the healthy human microbiota is highly diverse and carries “functional redundancy, the capacity for multiple microbes within the same ecosystem to carry out the same tasks.” Consequently, it has a moderate ability to withstand antibiotic-induced stress and to recover from it. However, because we all have a microbiota that is uniquely shaped by our environment and by other factors that are less well understood, this exclusivity means that it is not yet possible to predict individual responses to antimicrobial exposure. Furthermore, evidence indicates that disturbance of our microbial ecosystems at critical points in development (in particular, early childhood), may result in long-lasting damage that is not easily reversible and may lead to later susceptibility to chronic diseases such as inflammatory bowel disease, asthma, atopy, diabetes, obesity, and even autism.1,2

While it is often difficult to understand the extent to which microbiota damage may have concomitant detrimental effects on human health, we can look to a clear example where microbiota collapse is the underlying cause of disease. Clostridium difficile infection (CDI). The circumstances that give rise to CDI usually reflect collateral damage on the gut microbiota brought about by incidental antibiotic use, which allows C. difficile to proliferate and thrive without a healthy microbiota to regulate its expansion.2 Because the treatment for CDI often further antimicrobial exposure, either oral vancomycin or metronidazole, it is not surprising that the infection can recur, and a vicious cycle of pathogen expansion followed by antimicrobial suppression (but not clearance) can ensue.2 The ability of faecal microbial therapy (FMT, or stool transplant) to rapidly and effectively clear infection and cure disease, even in recalcitrant cases,2 is a clear indication of the power of the microbiota in the restoration of health. We and others have made steps to refine this somewhat primitive procedure through

Antimicrobials, and in particular those that are broad-spectrum in nature, are never simply targeted towards pathogens; in the battlefield of infection these drugs inflict heavy collateral damage on the indigenous microbiota.

the selection of particular health-associated gut microbes for the development of targeted, pure-cultured “Microbial Ecosystem Therapeutics.” (MET) thereby improving safety, controllability, and overall acceptability.1,3 MET could be administered alongside nutritional counselling to advise patients on healthy eating for the tailored management and maintenance of their beneficial colonic microbes. Harnessing the microbiome to treat disease and maintain health is thus the next step in the journey into a new era of medicine. While physicians have already begun to recognise the importance of antimicrobial stewardship and to adjust their perception of microbes as potentially life saving, there is still much work to be done to educate the general public in this respect. It is time to shift emphasis from the common perception that ‘the only good germ is a dead germ’, and instead focus on elucidating the beneficial effects that can result from wise management of our microbiome. Reduced patient persistence on unnecessary antibiotic therapy will be a happy consequence of this new understanding.

CONCLUSION

Antimicrobials will always have an important place in medicine, but their use may need to become more limited and defined. With more attention focused on targetted approaches to pathogen removal, we can lessen the adverse effects of antibiotics, both in terms of reducing antibiotic resistance and in reducing collateral damage inflicted on our microbiome. In the future, rather than serving as active contributors to the problem by implementing instruments of escalating host-versus-microbe warfare such as antibiotics, physicians may instead be required to be the brokers of peace agreements within the bodies of their patients, through new strategies involving manipulation and fine tuning of the microbiota rather than its destruction.

Emma Allen-Vercoe, Associate Professor, Department of Molecular and Cellular Biology, University of Guelph, Guelph, Canada

Elaine O Petrof, Assistant Professor, Department of Medicine, Kingston General Hospital, Queen’s University, Kingston, Ontario, Canada

Provenance: Commissioned; externally peer reviewed.

DOI: 10.22039/2014/197757

REFERENCES


ADDRESS FOR CORRESPONDENCE

Emma Allen-Vercoe
Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario N1G 2W1, Canada.
E-mail: eav@uoguelph.ca